6-HO-DMT

6-HO-DMT
臨床資料
其他名稱	6-HDMT; 6-HO-DMT; 6-OH-DMT; 6-Hydroxy-N,N-dimethyltryptamine
藥物類別	Serotonin receptor modulator
ATC碼	未分配;
識別資訊
	IUPAC命名法 3-[2-(dimethylamino)ethyl]-1H-indol-6-ol; ;
CAS號	1476-33-1
PubChem CID	15124;
ChemSpider	14396;
ChEMBL	ChEMBL382750;
CompTox Dashboard (EPA)	DTXSID70163752 ;
化學資訊
化學式	C12H16N2O
摩爾質量	204.27 g·mol−1
3D模型（JSmol）	交互式圖像;
	SMILES CN(C)CCC1=CNC2=C1C=CC(=C2)O;
	InChI InChI=1S/C12H16N2O/c1-14(2)6-5-9-8-13-12-7-10(15)3-4-11(9)12/h3-4,7-8,13,15H,5-6H2,1-2H3; Key:WUQMRWPLIMXBDX-UHFFFAOYSA-N;

6-HO-DMT或6-羥基-DMT，化學式為C₁₂H₁₆N₂O，化學名為6-羥基-N,N-二甲基色胺，是迷幻藥物二甲基色胺家族的一種血清素受體。^[1]^[2]^[3]^[4]它是齧齒動物體內DMT的主要代謝產物，也是人類體內DMT的次要代謝產物。^[3]^[5]它的log P計算值為2.4，^[6]與之對比，4-HO-DMT和5-HO-DMT的log P計算值分別為2.1^[7]和1.2^[8]。

參考文獻

^ Shulgin, Alexander; Shulgin, Ann (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252."
^ Shulgin AT. Basic Pharmacology and Effects. Laing RR (編). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. 2003: 67–137 [1 February 2025]. ISBN 978-0-12-433951-4.
^ ^3.0 ^3.1 Brimblecombe RW, Pinder RM. Indolealkylamines and Related Compounds. Hallucinogenic Agents. Bristol: Wright-Scientechnica. 1975: 98–144. ISBN 978-0-85608-011-1. OCLC 2176880. OL OL4850660M 請檢查|ol=值 (幫助).
^ Rosenberg DE, Isbell H, Miner EJ. Comparison of a placebo, N-dimethyltryptamine, and 6-hydroxy-N-dimethyltryptamine in man. Psychopharmacologia. February 1963, 4: 39–42. PMID 14050410. doi:10.1007/BF00429362.
^ Barker SA, Monti JA, Christian ST. N, N-dimethyltryptamine: an endogenous hallucinogen. International Review of Neurobiology. 1981, 22: 83–110. ISBN 978-0-12-366822-6. PMID 6792104. doi:10.1016/s0074-7742(08)60291-3.
^ 3-(2-(Dimethylamino)ethyl)-1H-indol-6-ol. PubChem. [5 November 2025].
^ Psilocin. PubChem. [5 November 2025].
^ Bufotenine. PubChem. [5 November 2025].

外部連結

6-HO-DMT - Isomer Design

[TiHKAL-1] Shulgin, Alexander; Shulgin, Ann (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252."

[Shulgin_2003-2] Shulgin AT. Basic Pharmacology and Effects. Laing RR (編). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. 2003: 67–137 [1 February 2025]. ISBN 978-0-12-433951-4.

[Brimblecombe_1975-3] 3.0 ^3.1 Brimblecombe RW, Pinder RM. Indolealkylamines and Related Compounds. Hallucinogenic Agents. Bristol: Wright-Scientechnica. 1975: 98–144. ISBN 978-0-85608-011-1. OCLC 2176880. OL OL4850660M 請檢查|ol=值 (幫助).

[Rosenberg_1963-4] Rosenberg DE, Isbell H, Miner EJ. Comparison of a placebo, N-dimethyltryptamine, and 6-hydroxy-N-dimethyltryptamine in man. Psychopharmacologia. February 1963, 4: 39–42. PMID 14050410. doi:10.1007/BF00429362.

[Barker_1981-5] Barker SA, Monti JA, Christian ST. N, N-dimethyltryptamine: an endogenous hallucinogen. International Review of Neurobiology. 1981, 22: 83–110. ISBN 978-0-12-366822-6. PMID 6792104. doi:10.1016/s0074-7742(08)60291-3.

[PubChem-6] 3-(2-(Dimethylamino)ethyl)-1H-indol-6-ol. PubChem. [5 November 2025].

[PubChem-Psilocin-7] Psilocin. PubChem. [5 November 2025].

[PubChem-Bufotenin-8] Bufotenine. PubChem. [5 November 2025].

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]